Abstract:Tumorogenesis is characterized by the unregulated proliferation of cells, which is the consequence of dysregulated cell division mechanisms. To ensure the rapid multiplication and invasion, tumor tend to create unique tumor microenvironment (TME) benefiting its own progression. As abnormal component in the body, figuring out how to escape from the supervision and attack of immune system is the key of tumor survival. Angiogenesis, which is mainly triggered by the stimulation of vascular endothelial growth factor (VEGF), is one of its solutions. Characterized by hypoxia, most type of tumor cells significantly upregulate VEGF, which stimulates active construction of tumor neovascularization. [1][2][3] However, the newly-formed tumor blood vessels show series of abnormalities, including increased luminal resistance, increased endothelial permeability and limited blood flow caused by defects in structure. [4] The features above are beneficial to the tumor growth and metastasis, as well as immune evasion, inducing resistance to immunotherapy. It was reported that anti-angiogenesis therapy has been seen as a promising strategy to enhance tumor immune response, which contributes to improve immunosuppressive TME and helps with anti-tumor effects by immune system. [5][6][7] The relation between angiogenesis and immune response was revealed in gene and transcriptomic level. Kurmyshkina et al. focused on the difference of transcriptomic landscapes between early-stage invasive cervical carcinoma (CeCa) and cervical intraepithelial neoplastic lesions (CIN). The authors found that innate immune pathways in early-stage CeCa were significantly upregulated in response to the infection of human papillomavirus, compared with CIN as precursor lesions. The tumors with active immune infiltration showed a more differentiated phenotype, while the ones with increased expression of genes associated with angiogenesis were related to exacerbation of de-differentiation and epithelial-to-mesenchymal transition. As reported, anti-angiogenesis therapy was expected to improve immune evasion and enhance immune infiltration. Shafqat et al. summarized previous studies which focused on tumor angiogenesis and coagulation exert suppressive effects on anti-tumor immune response. Both of them mediates the impacts above through specific mechanisms ultimately leading to the reprogramming of TME. Whether the usage of anti-angiogenic therapies to achieve vascular normalization and ACEi/ARBs to achieve stromal normalization targeting angiogenesis, or anticoagulants targeting coagulation, showed similar result of limit tumor progression and transform TME to favor immune response against tumors. Also, they both demonstrated the efficacy of enhance immunotherapy while combining with ICIs, despite the heterogeneity of tumor types still needs to be considered in the conjunction. It is natural to associate angiogenesis with prognosis since its influence on tumor invasion and progression. Li et al. developed an advanced machine learning model to evaluate the prognosis and therapy response of breast cancer based on several genes related to vascular mimicry (VM), the performance of which continuously exceeds that of traditional ones. The tumor group received higher VM scores than the normal group. The high-risk group showed higher level of tumor mutation burden (TMB) and higher mutation rate of tumor suppressor genes, and higher level of immune escape suggesting poor response to immunotherapy at the same time. Meanwhile, the low-risk group appeared more favorable response to immune checkpoint blockage. Eventually, the authors identified several promising chemotherapy drugs to which was VM related genes sensitive.To summarize, the studies above introduce some latest advances in the roles of angiogenesis and immune response in TME of solid tumors, and hopefully contribute to the further explorations of immunotherapy enhancer. We would like to acknowledge the invaluable support of all authors, reviewers and the editor team during the topic preparation process. We are looking forward to significant breakthroughs in the approach of sensitizing immunotherapy through anti-angiogenesis agents to emerge soon.

Remodeling of Tumor Stroma and Response to Therapy

License for destruction: tumor-specific cytokine targeting

The tumor stroma as mediator of drug resistance--a potential target to improve cancer therapy?

Strategies of targeting pathological stroma for enhanced antitumor therapies

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site

Targeting The Tumor Microenvironment For Enhancing Chemotherapy In Hematologic Malignancies

TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective"

Advances in tumor stroma-based targeted delivery

Impact of stroma remodeling on forces experienced by cancer cells and stromal cells within a pancreatic tumor tissue

Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression

Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited

Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor, volume III

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Tumor Microenvironment and Tumor Targeting Therapy

Tumor-associated stromal cells as key contributors to the tumor microenvironment

Therapy-induced microenvironmental changes in cancer

Microenvironmental regulation of therapeutic response in cancer

Rebuilding the microenvironment of primary tumors in humans: a focus on stroma